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ABSTRACT
Introduction: Insulin resistance has a strong relationship with the incidence of type II diabetes. 
It also has a direct relationship with other risk factors of diabetes, which together are known 
as metabolic syndrome. The aim of this study was to investigate the relationship between 
insulin resistance and hypertension. Materials and Methods: In this historical cohort study, 
90 patients were divided into three different groups: those without hypertension, those with 
controlled hypertension, and those with uncontrolled hypertension. Systolic and diastolic blood 
pressure, body mass index, and laboratory test results such as cholesterol, triglycerides, low-
density lipoprotein, high-density lipoprotein, fasting plasma glucose, and fasting plasma insulin 
were compared among the three groups. Data were analyzed with t-tests and the analysis of 
variance test, which were performed using statistical package for the social sciences version 20 
software. Results: Age and sex were the same among the three groups; however, BMI, systolic 
blood pressure, and diastolic blood pressure in the uncontrolled-hypertension group were higher 
than in the controlled-hypertension and without-hypertension groups (P<0.05). Lipid profile 
(P<0.05), creatinine (P=0.77), and uric acid (P=0.233) were not significantly different among the 
groups, although fasting plasma insulin (P=0.012) and homeostatic model assessment of insulin 
resistance (P=0.038) were significantly higher in the uncontrolled-hypertension group than in the 
other groups. Conclusion: Homeostasis model assessment of insulin resistance in patients with 
uncontrolled hypertension was higher than in patients with controlled hypertension and those 
without hypertension. Therefore, homeostatic model assessment of insulin resistance can be 
used as a predictive clinical test for the early diagnosis of diabetes in patients with uncontrolled 
hypertension.
INTRODUCTION
Insulin resistance (IR) plays a pathophysiological role in 
type II diabetes. It is also directly related to obesity, hy-
pertension, coronary artery diseases, dyslipidemia, and 
other disorders that are together known as metabolic syn-
drome (1, 2). Because of the rising worldwide incidence of 
obesity, the risks of type II diabetes and cardiovascular prob-
lems are increasing, so developing methods for evaluating 
and determining the nature of IR is crucial.
One of the most useful methods for evaluating IR is the ho-
meostatic model assessment (HOMA) indicators, which quickly 
measure glucose and insulin (3). Glucose intolerance and disor-
ders in fat profiles are related to insulin resistance, and because 
hypertension is one of the most important factors in cardiovascu-
lar diseases, there is no proven relation between them (4). Now, 
even IR is considered a prognostic factor for hypertension (5).
Therefore, the aim of this study was to evaluate IR in 
patients with hypertension.
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MATERIALS AND METHODS
In this historical cohort study, the sample population con-
sisted of 90 patients who were referred to the nonprofit and 
governmental hospitals in Yazd, Iran. They were divided 
into three groups those without hypertension, those with 
controlled hypertension, and those with uncontrolled hy-
pertension by the easy access sampling method. Those who 
had a history of systemic disease, those who used alcohol, 
those who abused drugs, and those who were smokers were 
excluded from the study. Data were collected by clinicians. 
Blood pressure was measured twice and registered by one 
instrument. Then, fasting blood sugar was measured after 14 
hours. After that, half of the blood samples were put in -20 
ºC and frozen after serum separation. Next, tests were per-
formed on the other half of blood samples to measure uric 
acid, glucose, triglycerides, low-density lipoprotein cho-
lesterol (LDL-C), and high-density lipoprotein cholesterol 
(HDL-C). Then, an IR test was performed in the hospital 
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on all samples. Cholesterol, triglycerides, and HDL-C were 
determined using enzymatic methods (Parsazmun, Karaj, 
Iran). LDL-C was calculated using the Friedewald formu-
la (6) Insulin and C-peptide concentrations were deter-
mined by the radioimmunoassay technique (Immunotech, 
Prague, Czech Republic). Data were analyzed with statisti-
cal package for the social sciences (SPSS) version 20 soft-
ware and with t-tests and the analysis of variance (ANOVA) 
test. HOMA-IR was calculated as follows: [Fasting Plas-
ma Glucose (FPG) (mg/dl) × Fasting Plasma Insulin (FPI) 
(mU/L)]/405 (7).
RESULTS
Patients were divided into three groups for assessment of 
laboratory test results and HOMA-IR. Patient age (mean ± 
standard deviation) in the without-hypertension group was 
49.17 ± 3.65 years; patient age in the controlled-hyperten-
sion group was 50.35 ± 3.02 years; and patient age in the 
uncontrolled-hypertension group was 51.11 ± 2.95 years. 
The ANOVA statistical test showed no significant differ-
ences in age among the three groups (P>0.05). In addi-
tion, by Fisher’s exact test, no significant differences in 
sex were observed among the three groups (P>0.05). Body 
mass index (BMI) in patients with uncontrolled hyperten-
sion was significantly higher than for patients in the other 
groups (P=0.048). Systolic blood pressure in patients with 
 uncontrolled hypertension was 14.24 ± 2.01 mmHg, which 
was higher than for patients in the other groups (P=0.0). 
Diastolic blood pressure in patients with uncontrolled hy-
pertension was also significantly higher than for patients in 
the other groups (P=0.001). Fasting glucose in patients with 
uncontrolled hypertension was 99.84 ± 1.52 mg/dL, where-
as in patients with controlled hypertension and in patients 
without hypertension, the levels were 100.27± 1.43 mg/
dL and 95.82 ± 1.59 mg/dL, respectively. The ANOVA 
test showed no significant differences among the groups 
(P=0.35). Serum insulin in patients with uncontrolled hy-
pertension was 3.48 ± 0.71 µU/mL, whereas in patients with 
controlled hypertension and in patients without hyperten-
sion, the levels were 3.68 ± 0.51 µU/mL and 3.83 ± 0.48 
µU/mL, respectively. Serum insulin levels in patients with 
uncontrolled hypertension were not significantly different 
(P=0.112) from patients with controlled hypertension and 
patients without hypertension. Cholesterol (P=0.13), tri-
glycerides (P=0.996), LDL (P=0.62), and HDL (P= 0.051) 
were significantly different among the three groups. Cre-
atinine (P=0.77) and uric acid (P=0.239) were not signifi-
cantly different among the three groups. HOMA was mea-
sured as a major parameter for assessing insulin resistance. 
HOMA in patients with uncontrolled hypertension was 1.35 
± 0.02, whereas these scores in patients with controlled hy-
pertension and in patients without hypertension were 0.91 ± 
0.007 and 0.92 ± 0.012, respectively.
Table 1. Demographic variable in three groups
Variables Without hypertension 
(n=29)
Controlled hypertension 
(n=31)
Uncontrolled hypertension 
(n=33)
P‑value
Age (years) 49.17±3.65 50.35±3.02 51.11±2.95 0.665*
Sex
Men (percent) 10 (29) 12 (34) 13 (37) 0.835**
Women (percent) 13 (24) 21 (38) 21 (38)
Body mass index (kg/m2) 25.21±2.56 28.4±2.69 29.41±1.89 0.048*
Systolic blood pressure (mmHg) 11.33±1.29 12.03±1.82 14.24±2.01 0.000*
Diastolic blood pressure (mmHg) 7.42±1.24 7.93±1.84 8.95±1.74 0.001*
* Analysis of variance test; ** Fisher’s exact test
Table 2. Laboratory findings in three groups
Variables Without hypertension 
(n=29)
Controlled hypertension 
(n=31)
Uncontrolled hypertension 
(n=33)
P‑value*
Serum insulin (µU/mL) 3.83±0.48 3.68±0.51 3.48±0.71 0.112
Glucose tolerance test (mg/dL) 125.79±4.21 128.68±4.95 127.26±4.54 0.103
Fasting glucose (mg/dL) 95.82±1.59 100.27±1.43 99.84±1.52 0.35
Cholesterol (mg/dL) 186.17±4.56 190.24±5.47 188.34±4.11 0.13
Triglycerides (mg/dL) 173.38±3.21 174.93±4.12 175.17±2.95 0.996
High-density lipoprotein (mg/dL) 41.3±0.68 47.06±0.94 45.78±0.75 0.051
Low-density lipoprotein (mg/dL) 121.31±2.64 125.8±2.94 123.9±2.01 0.62
Creatine (mg/dL) 0.89±0.04 0.93±0.05 0.92±0.08 0.77
Uric acid (mg/dL) 5.75±0.12 6.23±0.28 5.9±1.24 0.239
HOMA 0.92±0.012 0.91±0.007 1.35±0.02 0.038
(HOMA, homeostatic model assessment), * analysis of variance test
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DISCUSSION
Insulin is known to activate endothelial nitric oxide synthase 
to regulate glucose metabolism (8). IR after reducing nitric 
oxide secretion is responsible for endothelial impairments 
and cardiovascular diseases, such as hypertension (9). In this 
study, we found that HOMA-IR was significantly correlated 
with uncontrolled hypertension and was an independent fac-
tor for predicting IR in patients with uncontrolled hyperten-
sion, confirming a hypothesis that was frequently presented 
in previous clinical studies (10, 11). Some of these previ-
ous studies confirmed our hypotheses (10-12), other studies 
did not (13, 14). The pathogenesis of the relation between 
hypertension and IR has not been clearly identified. In our 
study, patients were matched by age and sex, but patients 
with uncontrolled hypertension had significantly higher 
BMI. Some studies suggested that visceral fat accumulation 
and central obesity were related to hypertension and insu-
lin resistance (15-17). In a clinical study, Sarafidis et al. re-
ported the effect of some anti-hypertensive drugs on insulin 
resistance (18). In our study, patients with controlled hyper-
tension had higher HOMA-IR scores than patients without 
hypertension. In other studies of patients with essential hy-
pertension, plasma level of free fatty acid was identified as a 
risk factor for insulin resistance (19-21). In a recent clinical 
study, Guo et al. reported that high free fatty acid levels were 
related to the incidence of hypertension and insulin resis-
tance, even if triglycerides, total count, HDL-C, and LDL-C 
were not significantly higher among different patient groups; 
this finding was the same as ours (22). It appears that many 
laboratory parameters can interface with IR and the patho-
genesis of hypertension. Determining the most accurate vari-
ables requires more detailed studies with larger sample sizes. 
This can be considered a limitation of our study.
CONCLUSION
In this study, we found that IR was significantly related to 
uncontrolled hypertension in the presence of matched fast-
ing glucose in different groups. Based on these findings and 
those of similar studies, the HOMA-IR index can be a valu-
able clinical predictor for the incidence of diabetes mellitus 
in patients with uncontrolled hypertension. Furthermore, 
controlling hypertension can decrease HOMA-IR levels and 
reduce the incidence of diabetes mellitus.
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